1
|
Sipol A, Hameister E, Xue B, Hofstetter J, Barenboim M, Öllinger R, Jain G, Prexler C, Rubio RA, Baldauf MC, Franchina DG, Petry A, Schmäh J, Thiel U, Görlach A, Cario G, Brenner D, Richter GH, Grünewald TG, Rad R, Wolf E, Ruland J, Sorensen PH, Burdach SE. MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress. Blood 2022; 139:1184-1197. [PMID: 33908607 PMCID: PMC11017790 DOI: 10.1182/blood.2020007932] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 04/02/2021] [Indexed: 11/20/2022] Open
Abstract
Cancer cells are in most instances characterized by rapid proliferation and uncontrolled cell division. Hence, they must adapt to proliferation-induced metabolic stress through intrinsic or acquired antimetabolic stress responses to maintain homeostasis and survival. One mechanism to achieve this is reprogramming gene expression in a metabolism-dependent manner. MondoA (also known as Myc-associated factor X-like protein X-interacting protein [MLXIP]), a member of the MYC interactome, has been described as an example of such a metabolic sensor. However, the role of MondoA in malignancy is not fully understood and the underlying mechanism in metabolic responses remains elusive. By assessing patient data sets, we found that MondoA overexpression is associated with worse survival in pediatric common acute lymphoblastic leukemia (ALL; B-precursor ALL [B-ALL]). Using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and RNA-interference approaches, we observed that MondoA depletion reduces the transformational capacity of B-ALL cells in vitro and dramatically inhibits malignant potential in an in vivo mouse model. Interestingly, reduced expression of MondoA in patient data sets correlated with enrichment in metabolic pathways. The loss of MondoA correlated with increased tricarboxylic acid cycle activity. Mechanistically, MondoA senses metabolic stress in B-ALL cells by restricting oxidative phosphorylation through reduced pyruvate dehydrogenase activity. Glutamine starvation conditions greatly enhance this effect and highlight the inability to mitigate metabolic stress upon loss of MondoA in B-ALL. Our findings give novel insight into the function of MondoA in pediatric B-ALL and support the notion that MondoA inhibition in this entity offers a therapeutic opportunity and should be further explored.
Collapse
Affiliation(s)
| | - Erik Hameister
- Institute of Clinical Chemistry and Pathobiochemistry, Technische Universität München, Munich, Germany
| | - Busheng Xue
- Children's Cancer Research Center, Department of Pediatrics
| | - Julia Hofstetter
- Cancer Systems Biology Group, Biochemistry and Molecular Biology, Universität Würzburg, Würzburg, Germany
| | | | - Rupert Öllinger
- Institute of Molecular Oncology and Functional Genomics, Technische Universität München, Munich, Germany
| | - Gaurav Jain
- Institute of Molecular Oncology and Functional Genomics, Technische Universität München, Munich, Germany
| | | | - Rebeca Alba Rubio
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
| | - Michaela C. Baldauf
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
| | - Davide G. Franchina
- Experimental and Molecular Immunology, Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
- Immunology and Genetics, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
| | - Andreas Petry
- Experimental and Molecular Pediatric Cardiology, German Heart Center Munich, Technische Universität München, Munich, Germany
| | - Juliane Schmäh
- Department of Pediatrics, Schleswig-Holstein University Medical Center, Kiel, Germany
| | - Uwe Thiel
- Children's Cancer Research Center, Department of Pediatrics
- Comprehensive Cancer Center (CCC) München and Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site, Munich, Germany
| | - Agnes Görlach
- Experimental and Molecular Pediatric Cardiology, German Heart Center Munich, Technische Universität München, Munich, Germany
- German Centre for Cardiovascular Research (DZHK), Munich Heart Alliance, Partner Site, Munich, Germany
| | - Gunnar Cario
- Department of Pediatrics, Schleswig-Holstein University Medical Center, Kiel, Germany
| | - Dirk Brenner
- Experimental and Molecular Immunology, Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
- Immunology and Genetics, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
- Odense Research Center for Anaphylaxis (ORCA), Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark
| | - Günther H.S. Richter
- Children's Cancer Research Center, Department of Pediatrics
- Comprehensive Cancer Center (CCC) München and Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site, Munich, Germany
| | - Thomas G.P. Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
- Comprehensive Cancer Center (CCC) München and Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site, Munich, Germany
| | - Roland Rad
- Institute of Molecular Oncology and Functional Genomics, Technische Universität München, Munich, Germany
- Comprehensive Cancer Center (CCC) München and Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site, Munich, Germany
| | - Elmar Wolf
- Cancer Systems Biology Group, Biochemistry and Molecular Biology, Universität Würzburg, Würzburg, Germany
| | - Jürgen Ruland
- Institute of Clinical Chemistry and Pathobiochemistry, Technische Universität München, Munich, Germany
- Comprehensive Cancer Center (CCC) München and Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site, Munich, Germany
| | - Poul H. Sorensen
- Children's Cancer Research Center, Department of Pediatrics
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
| | - Stefan E.G. Burdach
- Children's Cancer Research Center, Department of Pediatrics
- Comprehensive Cancer Center (CCC) München and Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site, Munich, Germany
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
| |
Collapse
|
2
|
Baldauf MC, Kapauer M, Joerger M, Flatz L, Rodriguez R, Frank S, Felbecker A, Hartmann-Fussenegger S, Hundsberger T. Pembrolizumab-Associated CD8 + Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. Neurol Neuroimmunol Neuroinflamm 2021; 8:8/4/e993. [PMID: 33824184 PMCID: PMC8023979 DOI: 10.1212/nxi.0000000000000993] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Accepted: 02/22/2021] [Indexed: 11/15/2022]
Affiliation(s)
- Michaela C Baldauf
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Monika Kapauer
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Markus Joerger
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Lukas Flatz
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Regulo Rodriguez
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Stephan Frank
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Ansgar Felbecker
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Susanne Hartmann-Fussenegger
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland
| | - Thomas Hundsberger
- From the Department of Neurology (M.C.B., M.K., A.F., S.H.-F.); Department of Hematology and Oncology (M.J.); Department of Dermatology (L.F.); Department of Pathology (R.R.), Cantonal Hospital, St. Gallen; Department of Pathology (S.F.), University Hospital, Basel; and Department of Neurology and Department of Hematology and Oncology (T.H.), Cantonal Hospital St. Gallen, Switzerland.
| |
Collapse
|
3
|
Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O, Mazor G, Varon M, Hölting TLB, Grossetête S, Gartlgruber M, Surdez D, Gerke JS, Ohmura S, Marchetto A, Dallmayer M, Baldauf MC, Stein S, Sannino G, Li J, Romero-Pérez L, Westermann F, Hartmann W, Dirksen U, Gymrek M, Anderson ND, Shlien A, Rotblat B, Kirchner T, Delattre O, Grünewald TGP. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nat Commun 2019; 10:4128. [PMID: 31511524 PMCID: PMC6739408 DOI: 10.1038/s41467-019-12071-2] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Accepted: 08/16/2019] [Indexed: 12/02/2022] Open
Abstract
Pediatric malignancies including Ewing sarcoma (EwS) feature a paucity of somatic alterations except for pathognomonic driver-mutations that cannot explain overt variations in clinical outcome. Here, we demonstrate in EwS how cooperation of dominant oncogenes and regulatory germline variants determine tumor growth, patient survival and drug response. Binding of the oncogenic EWSR1-FLI1 fusion transcription factor to a polymorphic enhancer-like DNA element controls expression of the transcription factor MYBL2 mediating these phenotypes. Whole-genome and RNA sequencing reveals that variability at this locus is inherited via the germline and is associated with variable inter-tumoral MYBL2 expression. High MYBL2 levels sensitize EwS cells for inhibition of its upstream activating kinase CDK2 in vitro and in vivo, suggesting MYBL2 as a putative biomarker for anti-CDK2-therapy. Collectively, we establish cooperation of somatic mutations and regulatory germline variants as a major determinant of tumor progression and highlight the importance of integrating the regulatory genome in precision medicine.
Collapse
Affiliation(s)
- Julian Musa
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Florencia Cidre-Aranaz
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Marie-Ming Aynaud
- INSERM U830, Équipe Labellisée LNCC Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France
| | - Martin F Orth
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Maximilian M L Knott
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Olivier Mirabeau
- INSERM U830, Équipe Labellisée LNCC Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France
| | - Gal Mazor
- Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Mor Varon
- Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Tilman L B Hölting
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Sandrine Grossetête
- INSERM U830, Équipe Labellisée LNCC Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France
| | - Moritz Gartlgruber
- Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Didier Surdez
- INSERM U830, Équipe Labellisée LNCC Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France
| | - Julia S Gerke
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Shunya Ohmura
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Aruna Marchetto
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Marlene Dallmayer
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Michaela C Baldauf
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Stefanie Stein
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Giuseppina Sannino
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Jing Li
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Laura Romero-Pérez
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Frank Westermann
- Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Wolfgang Hartmann
- Division of Translational Pathology, Gerhard-Domagk Institute of Pathology, University Hospital of Münster, Münster, Germany
| | - Uta Dirksen
- Department of Pediatric Hematology and Oncology, University Hospital of Essen, Essen, Germany
| | - Melissa Gymrek
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
- Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA, USA
| | - Nathaniel D Anderson
- Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Adam Shlien
- Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada
| | - Barak Rotblat
- Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Thomas Kirchner
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Olivier Delattre
- INSERM U830, Équipe Labellisée LNCC Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France
| | - Thomas G P Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
- German Cancer Consortium (DKTK), Partner site Munich, Munich, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
4
|
Dallmayer M, Li J, Ohmura S, Alba Rubio R, Baldauf MC, Hölting TLB, Musa J, Knott MML, Stein S, Cidre-Aranaz F, Wehweck FS, Romero-Pérez L, Gerke JS, Orth MF, Marchetto A, Kirchner T, Bach H, Sannino G, Grünewald TGP. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. Cell Death Dis 2019; 10:116. [PMID: 30741933 PMCID: PMC6370763 DOI: 10.1038/s41419-019-1372-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2018] [Revised: 01/16/2019] [Accepted: 01/17/2019] [Indexed: 12/17/2022]
Abstract
Ewing sarcoma (EwS) is an aggressive cancer characterized by chromosomal translocations generating fusions of the EWSR1 gene with ETS transcription factors (in 85% FLI1). EWSR1-FLI1 induces gene expression via binding to enhancer-like GGAA-microsatellites, whose activity correlates with the number of consecutive GGAA-repeats. Herein we investigate the role of the secretory neuropeptide CALCB (calcitonin-related polypeptide β) in EwS, which signals via the CGRP (calcitonin gene-related peptide) receptor complex, containing RAMP1 (receptor activity modifying protein 1) as crucial part for receptor specificity. Analysis of 2678 gene expression microarrays comprising 50 tumor entities and 71 normal tissue types revealed that CALCB is specifically and highly overexpressed in EwS. Time-course knockdown experiments showed that CALCB expression is tightly linked to that of EWSR1-FLI1. Consistently, gene set enrichment analyses of genes whose expression in primary EwS is correlated to that of CALCB indicated that it is co-expressed with other EWSR1-FLI1 target genes and associated with signatures involved in stemness and proliferation. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data for FLI1 and histone marks from EwS cell lines demonstrated that EWSR1-FLI1 binds to a GGAA-microsatellite close to CALCB, which exhibits characteristics of an active enhancer. Reporter assays confirmed the strong EWSR1-FLI1- and length-dependent enhancer activity of this GGAA-microsatellite. Mass spectrometric analyses of EwS cell culture supernatants demonstrated that CALCB is secreted by EwS cells. While short-term RNA interference-mediated CALCB knockdown had no effect on proliferation and clonogenic growth of EwS cells in vitro, its long-term knockdown decreased EwS growth in vitro and in vivo. Similarly, knockdown of RAMP1 reduced clonogenic/spheroidal growth and tumorigenicity, and small-molecule inhibitors directed against the RAMP1-comprising CGRP receptor reduced growth of EwS. Collectively, our findings suggest that CALCB is a direct EWSR1-FLI1 target and that targeting the CALCB/RAMP1 axis may offer a new therapeutic strategy for inhibition of EwS growth.
Collapse
Affiliation(s)
- Marlene Dallmayer
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Jing Li
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Shunya Ohmura
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Rebeca Alba Rubio
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Michaela C Baldauf
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Tilman L B Hölting
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Julian Musa
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Max M L Knott
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany.,Institute of Pathology of the LMU Munich, Munich, Germany
| | - Stefanie Stein
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Florencia Cidre-Aranaz
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Fabienne S Wehweck
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany.,Institute of Pathology of the LMU Munich, Munich, Germany
| | - Laura Romero-Pérez
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Julia S Gerke
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Martin F Orth
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Aruna Marchetto
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Thomas Kirchner
- Institute of Pathology of the LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Horacio Bach
- Department of Medicine, Division of Infectious Diseases, and IIRC Antibody Engineering and Proteomics facility, University of British Columbia, Vancouver, BC, Canada
| | - Giuseppina Sannino
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Thomas G P Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany. .,Institute of Pathology of the LMU Munich, Munich, Germany. .,German Cancer Consortium (DKTK), Heidelberg, Germany. .,German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
5
|
Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TLB, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MML, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TGP. Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. Int J Cancer 2018; 144:859-867. [DOI: 10.1002/ijc.31903] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Accepted: 09/19/2018] [Indexed: 01/08/2023]
Affiliation(s)
- Martin F. Orth
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Julia S. Gerke
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Thomas Knösel
- Institute of Pathology; Faculty of Medicine, LMU Munich; Munich Germany
| | | | - Julian Musa
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Rebeca Alba-Rubio
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Stefanie Stein
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Tilman L. B. Hölting
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Florencia Cidre-Aranaz
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Laura Romero-Pérez
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Marlene Dallmayer
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Michaela C. Baldauf
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Aruna Marchetto
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Giuseppina Sannino
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Maximilian M. L. Knott
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
- Institute of Pathology; Faculty of Medicine, LMU Munich; Munich Germany
| | - Fabienne Wehweck
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
- Institute of Pathology; Faculty of Medicine, LMU Munich; Munich Germany
| | - Shunya Ohmura
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Jing Li
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
| | - Michiyuki Hakozaki
- Department of Orthopaedic Surgery; Fukushima Medical University School of Medicine; Fukushima Japan
| | - Thomas Kirchner
- Institute of Pathology; Faculty of Medicine, LMU Munich; Munich Germany
- German Cancer Consortium (DKTK), partner site Munich; Germany
- German Cancer Research Center (DKFZ); Heidelberg Germany
| | - Thomas Dandekar
- Functional Genomics and Systems Biology Group, Department of Bioinformatics, Biocenter; Am Hubland, Würzburg Germany
| | - Elke Butt
- Institute for Experimental Biomedicine II, University Clinic of Würzburg; Würzburg Germany
| | - Thomas G. P. Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology; Institute of Pathology, Faculty of Medicine, LMU Munich; Munich Germany
- Institute of Pathology; Faculty of Medicine, LMU Munich; Munich Germany
- German Cancer Consortium (DKTK), partner site Munich; Germany
- German Cancer Research Center (DKFZ); Heidelberg Germany
| |
Collapse
|
6
|
Baldauf MC, Gerke JS, Kirschner A, Blaeschke F, Effenberger M, Schober K, Rubio RA, Kanaseki T, Kiran MM, Dallmayer M, Musa J, Akpolat N, Akatli AN, Rosman FC, Özen Ö, Sugita S, Hasegawa T, Sugimura H, Baumhoer D, Knott MML, Sannino G, Marchetto A, Li J, Busch DH, Feuchtinger T, Ohmura S, Orth MF, Thiel U, Kirchner T, Grünewald TGP. Systematic identification of cancer-specific MHC-binding peptides with RAVEN. Oncoimmunology 2018; 7:e1481558. [PMID: 30228952 PMCID: PMC6140548 DOI: 10.1080/2162402x.2018.1481558] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 05/21/2018] [Accepted: 05/21/2018] [Indexed: 02/03/2023] Open
Abstract
Immunotherapy can revolutionize anti-cancer therapy if specific targets are available. Immunogenic peptides encoded by cancer-specific genes (CSGs) may enable targeted immunotherapy, even of oligo-mutated cancers, which lack neo-antigens generated by protein-coding missense mutations. Here, we describe an algorithm and user-friendly software named RAVEN (Rich Analysis of Variable gene Expressions in Numerous tissues) that automatizes the systematic and fast identification of CSG-encoded peptides highly affine to Major Histocompatibility Complexes (MHC) starting from transcriptome data. We applied RAVEN to a dataset assembled from 2,678 simultaneously normalized gene expression microarrays comprising 50 tumor entities, with a focus on oligo-mutated pediatric cancers, and 71 normal tissue types. RAVEN performed a transcriptome-wide scan in each cancer entity for gender-specific CSGs, and identified several established CSGs, but also many novel candidates potentially suitable for targeting multiple cancer types. The specific expression of the most promising CSGs was validated in cancer cell lines and in a comprehensive tissue-microarray. Subsequently, RAVEN identified likely immunogenic CSG-encoded peptides by predicting their affinity to MHCs and excluded sequence identity to abundantly expressed proteins by interrogating the UniProt protein-database. The predicted affinity of selected peptides was validated in T2-cell peptide-binding assays in which many showed binding-kinetics like a very immunogenic influenza control peptide. Collectively, we provide an exquisitely curated catalogue of cancer-specific and highly MHC-affine peptides across 50 cancer types, and a freely available software (https://github.com/JSGerke/RAVENsoftware) to easily apply our algorithm to any gene expression dataset. We anticipate that our peptide libraries and software constitute a rich resource to advance anti-cancer immunotherapy.
Collapse
Affiliation(s)
- Michaela C Baldauf
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Julia S Gerke
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Andreas Kirschner
- Children's Cancer Research Center, Technische Universität München (TUM), Munich, Germany
| | - Franziska Blaeschke
- Department of Pediatrics, Dr. von Hauner'sches Children's Hospital, LMU Munich, Munich, Germany
| | - Manuel Effenberger
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Kilian Schober
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Rebeca Alba Rubio
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | | | - Merve M Kiran
- Department of Pathology, Medical Faculty, Yildirim Beyazit University, Ankara, Turkey
| | - Marlene Dallmayer
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Julian Musa
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Nurset Akpolat
- Department of Pathology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey
| | - Ayse N Akatli
- Department of Pathology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey
| | - Fernando C Rosman
- Department for Pathology, Hospital Municipal Jesus, Rio de Janeiro, Brazil
| | - Özlem Özen
- Department of Pathology, Medical Faculty, Başkent University Hospital, Ankara, Turkey
| | - Shintaro Sugita
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Tadashi Hasegawa
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Haruhiko Sugimura
- Department of Tumor Pathology, Hamamatsu School of Medicine, Hamamatsu, Japan
| | - Daniel Baumhoer
- Bone Tumor Reference Center, Institute of Pathology of the University Hospital of Basel, Basel, Switzerland
| | - Maximilian M L Knott
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Giuseppina Sannino
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Aruna Marchetto
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Jing Li
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Dirk H Busch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany
| | - Tobias Feuchtinger
- Department of Pediatrics, Dr. von Hauner'sches Children's Hospital, LMU Munich, Munich, Germany
| | - Shunya Ohmura
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Martin F Orth
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany
| | - Uwe Thiel
- Children's Cancer Research Center, Technische Universität München (TUM), Munich, Germany
| | - Thomas Kirchner
- Faculty of Medicine, Institute of Pathology, LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Partner Site Munich, Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Thomas G P Grünewald
- Faculty of Medicine, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, LMU Munich, Munich, Germany.,Faculty of Medicine, Institute of Pathology, LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Partner Site Munich, Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
7
|
Baldauf MC, Gerke JS, Orth MF, Dallmayer M, Baumhoer D, de Alava E, Hartmann W, Kirchner T, Grünewald TGP. Are EWSR1-NFATc2-positive sarcomas really Ewing sarcomas? Mod Pathol 2018; 31:997-999. [PMID: 29895896 DOI: 10.1038/s41379-018-0009-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 12/19/2017] [Indexed: 11/09/2022]
Affiliation(s)
- Michaela C Baldauf
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Julia S Gerke
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Martin F Orth
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Marlene Dallmayer
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Daniel Baumhoer
- Bone Tumour Reference Center, Institute of Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Enrique de Alava
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, CIBERONC, Seville, Spain
| | - Wolfgang Hartmann
- Gerhard-Domagk-Institute for Pathology, University Hospital Münster, Westfalian Wilhelms University, Münster, Germany
| | - Thomas Kirchner
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Thomas G P Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany. .,Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany. .,German Cancer Consortium (DKTK), Heidelberg, Germany. .,German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
8
|
Baldauf MC, Orth MF, Dallmayer M, Marchetto A, Gerke JS, Rubio RA, Kiran MM, Musa J, Knott MML, Ohmura S, Li J, Akpolat N, Akatli AN, Özen Ö, Dirksen U, Hartmann W, de Alava E, Baumhoer D, Sannino G, Kirchner T, Grünewald TGP. Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. Oncotarget 2017; 9:1587-1601. [PMID: 29416716 PMCID: PMC5788584 DOI: 10.18632/oncotarget.20098] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Accepted: 07/23/2017] [Indexed: 12/26/2022] Open
Abstract
Ewing sarcoma is an undifferentiated small-round-cell sarcoma. Although molecular detection of pathognomonic EWSR1-ETS fusions such as EWSR1-FLI1 enables definitive diagnosis, substantial confusion can arise if molecular diagnostics are unavailable. Diagnosis based on the conventional immunohistochemical marker CD99 is unreliable due to its abundant expression in morphological mimics. To identify novel diagnostic immunohistochemical markers for Ewing sarcoma, we performed comparative expression analyses in 768 tumors representing 21 entities including Ewing-like sarcomas, which confirmed that CIC-DUX4-, BCOR-CCNB3-, EWSR1-NFATc2-, and EWSR1-ETS-translocated sarcomas are distinct entities, and revealed that ATP1A1, BCL11B, and GLG1 constitute specific markers for Ewing sarcoma. Their high expression was validated by immunohistochemistry and proved to depend on EWSR1-FLI1-binding to highly active proximal super-enhancers. Automated cut-off-finding and combination-testing in a tissue-microarray comprising 174 samples demonstrated that detection of high BCL11B and/or GLG1 expression is sufficient to reach 96% specificity for Ewing sarcoma. While 88% of tested Ewing-like sarcomas displayed strong CD99-immunoreactivity, none displayed combined strong BCL11B- and GLG1-immunoreactivity. Collectively, we show that ATP1A1, BCL11B, and GLG1 are EWSR1-FLI1 targets, of which BCL11B and GLG1 offer a fast, simple, and cost-efficient way to diagnose Ewing sarcoma by immunohistochemistry. These markers may significantly reduce the number of misdiagnosed patients, and thus improve patient care.
Collapse
Affiliation(s)
- Michaela C Baldauf
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Martin F Orth
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Marlene Dallmayer
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Aruna Marchetto
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Julia S Gerke
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Rebeca Alba Rubio
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Merve M Kiran
- Department of Pathology, Medical Faculty, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Julian Musa
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Maximilian M L Knott
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Shunya Ohmura
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Jing Li
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Nusret Akpolat
- Department of Pathology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey
| | - Ayse N Akatli
- Department of Pathology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey
| | - Özlem Özen
- Department of Pathology, Başkent University Hospital, Ankara, Turkey
| | - Uta Dirksen
- Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany
| | - Wolfgang Hartmann
- Gerhard-Domagk-Institute for Pathology, University Hospital Münster, Westfalian Wilhelms University, Münster, Germany
| | - Enrique de Alava
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, CIBERONC, Seville, Spain
| | - Daniel Baumhoer
- Bone Tumour Reference Center, Institute of Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Giuseppina Sannino
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Thomas Kirchner
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Thomas G P Grünewald
- Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.,Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
9
|
Kirschner A, Thiede M, Blaeschke F, Richter GH, Gerke JS, Baldauf MC, Grünewald TG, Busch DH, Burdach S, Thiel U. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens. Oncotarget 2016; 7:56584-56597. [PMID: 27447745 PMCID: PMC5302936 DOI: 10.18632/oncotarget.10647] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 05/30/2016] [Indexed: 01/23/2023] Open
Abstract
AIM Autologous as well as allogeneic CD8+ T cells transduced with tumor antigen specific T cell receptors (TCR) may cause significant tumor lysis upon adoptive transfer. Besides unpredictable life-threatening off-target effects, these TCRs may unexpectedly commit fratricide. We hypothesized lysosome-associated membrane glycoprotein 1 (LAMP1, CD107a) to be a marker for fratricide in TCR transgenic CD8+ T cells. METHODS We identified HLA-A*02:01/peptide-restricted T cells directed against ADRB3295. After TCR identification, we generated HLA-A*02:01/peptide restricted TCR transgenic T cells by retroviral transduction and tested T cell expansion rates as well as A*02:01/peptide recognition and ES killing in ELISpot and xCELLigence assays. Expansion arrest was analyzed via Annexin and CD107a staining. Results were compared to CHM1319-TCR transgenic T cells. RESULTS Beta-3-adrenergic receptor (ADRB3) as well as chondromodulin-1 (CHM1) are over-expressed in Ewing Sarcoma (ES) but not on T cells. TCR transgenic T cells demonstrated HLA-A*02:01/ADRB3295 mediated ES recognition and killing in ELISpot and xCELLigence assays. 24h after TCR transduction, CD107a expression correlated with low expansion rates due to apoptosis of ADRB3 specific T cells in contrast to CHM1 specific transgenic T cells. Amino-acid exchange scans clearly indicated the cross-reactive potential of HLA-A*02:01/ADRB3295- and HLA-A*02:01/CHM1319-TCR transgenic T cells. Comparison of peptide motive binding affinities revealed extended fratricide among ADRB3295 specific TCR transgenic T cells in contrast to CHM1319. CONCLUSION Amino-acid exchange scans alone predict TCR cross-reactivity with little specificity and thus require additional assessment of potentially cross-reactive HLA-A*02:01 binding candidates. CD107a positivity is a marker for fratricide of CD8+ TCR transgenic T cells.
Collapse
Affiliation(s)
- Andreas Kirschner
- Laboratory for Functional Genomics and Transplantation Biology, Departments of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Melanie Thiede
- Laboratory for Functional Genomics and Transplantation Biology, Departments of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Franziska Blaeschke
- Laboratory for Functional Genomics and Transplantation Biology, Departments of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
- Laboratory for Immunotherapy, Dr. von Hauner Children's Hospital, Medical center of the LMU Munich, Munich, Germany
| | - Günther H.S. Richter
- Laboratory for Functional Genomics and Transplantation Biology, Departments of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Julia S. Gerke
- Laboratory for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Michaela C. Baldauf
- Laboratory for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
| | - Thomas G.P. Grünewald
- Laboratory for Pediatric Sarcoma Biology, Institute of Pathology of the LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dirk H. Busch
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany
| | - Stefan Burdach
- Laboratory for Functional Genomics and Transplantation Biology, Departments of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Uwe Thiel
- Laboratory for Functional Genomics and Transplantation Biology, Departments of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
10
|
Abstract
Brush cytology for the routine microscopic examination of malignant pancreaticobiliary strictures has been shown to have a high degree of specificity but a sensitivity of less than 75%. We wanted to determine whether flow cytometric analysis for DNA content could increase the sensitivity of routine cytology in brushings from these strictures, especially in those patients with atypical cells noted by brush cytology but no definite tumor cells. Fifty-one sets of brushings were obtained from 48 patients in whom ERCP revealed pancreaticobiliary strictures. Specimens were obtained for both routine cytology and flow cytometry. Both studies were shown to have a sensitivity of 42% in diagnosing malignant strictures. The specificity was 92% for routine cytology and 77% for flow cytometry, with false-positive results obtained in one patient by the former technique and in three by the latter. When the studies were combined, so that the presence of either tumor cells or abnormal DNA content was diagnostic of malignancy, the sensitivity rose to 63%. However, the specificity fell to 69%. Routine cytology identified atypical cells in 13 patients with malignant strictures (39%). Flow cytometry identified abnormal DNA content in only six of these patients with atypical cytological specimens (46%). Although flow cytometry succeeded in identifying eight additional strictures as malignant, it was associated with a greater false-positive rate than was routine cytology. For patients with pancreatic carcinoma, increased survival was noted in those with a diploid cell population (mean, 8.9 months) as revealed by flow cytometry compared to those with aneuploid brushings (mean, 3.0 months). We conclude that the addition of flow cytometry for DNA content to routine cytology increases the diagnostic yield of brushings from pancreaticobiliary strictures. However, these results need to be interpreted together with the patient's history, ERCP, and other clinical findings in order to minimize false-positive results.
Collapse
Affiliation(s)
- M E Ryan
- Department of Gastroenterology, Marshfield Clinic, Wisconsin 54449
| | | |
Collapse
|
11
|
Rushing DA, Friedenberg WR, Baldauf MC, Broste S, Gehlsen JA, Kriesel DH, Koontz DP, Rodvold KA. High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma. Cancer 1991; 68:720-4. [PMID: 1649684 DOI: 10.1002/1097-0142(19910815)68:4<720::aid-cncr2820680409>3.0.co;2-r] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Fourteen patients with small cell carcinoma of the lung in relapse or with disease refractory to chemotherapy were treated with carmustine (BCNU) at doses of 600 to 1000 mg/m2 intravenously followed by autologous bone marrow transplantation. All patients previously were treated with cyclophosphamide, doxorubicin, vincristine, and etoposide. Seven of the 14 patients responded to the high-dose BCNU (50% response with 95% confidence limits ranging from 23% to 77%). Three patients had a complete response, and four had a partial response. Regrowth of tumor occurred within 60 days of treatment in the responding patients. Death occurred in six patients before the recovery of the platelet count to 50,000 cells/microliters. Although the response rate was high, the toxicity was excessive. In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy.
Collapse
Affiliation(s)
- D A Rushing
- Department of Oncology, Marshfield Clinic, WI 54449
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Meier PR, Baldauf MC. HIV among pregnant women: north central Wisconsin. Wis Med J 1989; 88:10-2. [PMID: 2588648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The incidence of infection by the human immunodeficiency virus (HIV) among pregnant women in north central Wisconsin is unknown. We devised and used an anonymous screening protocol to determine both the incidence of HIV infection and the rate of infection spread in this population. Our data demonstrate an extremely low incidence of HIV infection. Further, over the time periods studied, no clear evidence of an increase in the incidence of this severe infection could be demonstrated.
Collapse
|
13
|
Affiliation(s)
- J C Opitz
- Department of Pediatrics, Marshfield Clinic, WI 54449
| | | | | | | |
Collapse
|
14
|
Baldauf MC, Kriesel DH. Treating severe hemapheresis donor reactions. Transfusion 1984; 24:410. [PMID: 6485082 DOI: 10.1046/j.1537-2995.1984.24585017831.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
15
|
Abstract
Intradermal skin tests with a culture filtrate antigen of Micropolyspora faeni grown on a synthetic medium were performed on patients with farmers' lung disease (FLD) and well farmers with and without antibodies to a panel of FLD antigens. Seventy-five percent of the FLD patients, 79% of the well farmers with M. faeni antibody, and 5% of well farmers without M. faeni antibody had a 2+ or greater intradermal immediate skin-test reaction. Prausnitz-Küstner (P-K) reactions were positive using serum of M. faeni immediate skin test-positive FLD patients. IgG-rich fractions from a staphylococcal protein A-Sepharose column of such serum contained the sensitizing factor whereas IgG-depleted fractions did not. M. faeni-specific IgE could not be detected in serum by a polystyrene radioimmunoassay. Positive late-onset (6-hr) skin tests occurred only in FLD patients and farmers with precipitating antibody. Biopsy specimens of the 6-hr reactions revealed a generalized dermal and perivascular polymorphonuclear infiltrate with deposits of immunoglobulin and complement about blood vessels. The skin-sensitizing factor noted in FLD patients and well farmers with antibody is not disease specific. This factor appears to be associated with the IgG-rich fraction of serum, and its role in the pathogenesis of FLD is unclear.
Collapse
|
16
|
Abstract
Multilocular cyst of the kidney is an uncommon lesion. Approximately 70 cases are reported in the literature, with more than half occurring in children. The etiology and pathogenesis are not known, although the microscopic appearance in certain cases resembles that of Wilms' tumor. Three additional cases are presented and the literature is reviewed.
Collapse
|